Exploring Metabolomic Patterns in Type 2 Diabetes Mellitus and Response to Glucose-Lowering Medications-Review.
Mina ShahisavandiKan WangMohsen GhanbariAnke H Maitland-van der ZeePublished in: Genes (2023)
The spectrum of information related to precision medicine in diabetes generally includes clinical data, genetics, and omics-based biomarkers that can guide personalized decisions on diabetes care. Given the remarkable progress in patient risk characterization, there is particular interest in using molecular biomarkers to guide diabetes management. Metabolomics is an emerging molecular approach that helps better understand the etiology and promises the identification of novel biomarkers for complex diseases. Both targeted or untargeted metabolites extracted from cells, biofluids, or tissues can be investigated by established high-throughput platforms, like nuclear magnetic resonance (NMR) and mass spectrometry (MS) techniques. Metabolomics is proposed as a valuable tool in precision diabetes medicine to discover biomarkers for diagnosis, prognosis, and management of the progress of diabetes through personalized phenotyping and individualized drug-response monitoring. This review offers an overview of metabolomics knowledge as potential biomarkers in type 2 diabetes mellitus (T2D) diagnosis and the response to glucose-lowering medications.
Keyphrases
- mass spectrometry
- type diabetes
- magnetic resonance
- cardiovascular disease
- high throughput
- glycemic control
- liquid chromatography
- high resolution
- blood glucose
- ms ms
- high performance liquid chromatography
- capillary electrophoresis
- gas chromatography
- healthcare
- emergency department
- case report
- gene expression
- computed tomography
- multiple sclerosis
- single cell
- magnetic resonance imaging
- single molecule
- adipose tissue
- skeletal muscle
- endoplasmic reticulum stress
- electronic health record
- drug induced
- cell proliferation
- machine learning
- drug delivery
- data analysis
- gas chromatography mass spectrometry